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Rationale: The long-term evolution of patients with chest wall disease and chronic respiratory
failure treated with noninvasive home mechanical ventilation (NIHMV) is poorly known.
Objectives: The aim of this prospective observational study was to analyze the variables asso-
ciated with mortality in a cohort of chest wall disease patients with chronic respiratory failure
undergoing long-term follow-up after starting treatment with NIHMV.
Methods: Chest wall disease patients who began NIHMV between 1996 and 2005 were followed
up, with death as the primary outcome. The patients’ clinical characteristics, lung function,
and arterial blood gases were recorded at the start of treatment. Patients were seen and eval-
uated 1 month after starting NIHMV. The prognostic value of clinical and functional variables
were assessed by Cox regression analyses.
Main results: We included 110 patients, 61 with tuberculosis sequelae and 49 with kyphosco-
liosis. By the end of follow-up, 34 patients (28%) had died. The 5-year survival was 69% in those
with tuberculosis sequelae and 75% in kyphoscoliosis. PaCO2 50 mmHg at 1 month of home
ventilation and comorbidity (Charlson Index 3) were independent predictors of mortality.
Conclusion: Our results suggest that PaCO2 levels 50 mmHg at 1 month after starting nonin-
vasive home mechanical ventilation and the presence of comorbid conditions are risk factors
for mortality in patients with chest wall disease. The importance of early detection of subop-
timal home ventilation as well as comorbidities is highlighted.
ª 2010 Elsevier Ltd. All rights reserved.neumologia, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona,
93 2746083.
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1844 S. Martı´ et al.Introduction patients with oxygen saturation <90% during 30% of the*Includes 11 patients with post-polio kyphoscoliosis.  
COPD = chronic obstructive pulmonary disease; NIHMV = noninvasive home mechanical 
ventilation
Patients starting home mechanical ventilation 
1996-2005 
n=384 
Not included: 
Neuromuscular diseases* n=133 
COPD n=71
Obesity-hypoventilation syndrome n=65  
Chest wall diseases  
n=115 
Excluded from the study:  
Tracheostomy n=1 
NIHMV withdrawal (noncompliance) n=4
Study population 
n=110
Figure 1 Flow chart of patient enrollment.Noninvasive home mechanical ventilation (NIHMV) is indi-
cated in chest wall diseases (CWD) developing chronic
respiratory failure (CRF).1,2 Therefore, in a European
epidemiologic survey (Eurovent), CWD accounted for
approximately one-third of the indications for home
mechanical ventilation.3
After implementation of NIHMV in CWD patients with
CRF, improvements in hypoventilation symptoms4,5 and
arterial blood gases (ABG),6e10 and a reduction in hospital
admissions due to respiratory complications4,9 have been
shown. Despite these short-term favorable outcomes, the
long-term evolution of NIHMV in these patients is poorly
known. Survival in patients with CWD receiving NIHMV has
been estimated in 2 series.8,10 Leger et al.8 found that
nearly 80% of patients continue NIHMV at 3 years. In the
study by Simmonds et al.,10 this figure differed slightly
depending on the cause of CWD: 94% and 79% of patients
with tuberculosis sequelae and kyphoscoliosis, respec-
tively, continued NIHMV at 5 years.
The relationship between clinical and respiratory func-
tion variables and mortality in CWD patients undergoing
NIHMV remains to be defined. In a 10-year analysis from the
ANTADIR Observatory, prognostic factors of mortality were
evaluated in patients with tuberculosis sequelae and
kyphoscoliosis.11 However, less than 30% of these patients
were receiving NIHMV, and the authors did not perform
a separate analysis of this subsample. Taking into account
all patients, regardless of the therapy received, female
sex, younger age, a high body mass index, and higher PaO2
and PaCO2 values were all favorable independent prog-
nostic factors.11 Survival of patients with kyphoscoliosis12
and tuberculosis sequelae13 was also evaluated in the 2
Swedish studies mentioned above. In both studies, survival
was associated with the therapy applied (NIHMV or LTOT)
and this fact likely precluded the finding of associations
between other independent variables and mortality. This
paucity of evidence highlights the need for further studies
focused on CWD patients undergoing NIHMV and followed-
up on a long-term basis. Knowledge of prognostic factors
for mortality has clinical interest, since it may help to
improve the management of these patients.
The aim of the present study was to analyze the vari-
ables associated with mortality in a cohort of patients with
CWD and CRF undergoing long-term follow-up after starting
treatment with NIHMV.
Patients and methods
All adult patients (18 years) with CWDwho started NIHMV in
a teaching hospital (Vall dHebron Hospital, Barcelona, Spain)
were considered for inclusion in this prospective, observa-
tional study. Patients were enrolled between January 1996
and December 2005. The indication for NIHMV was based on
Spanish and international guidelines,1,14 including clinical
symptoms (dyspnea, fatigue, orthopnea, or morning
headache) and one of the following criteria: 1) stable
patients with chronic hypercapnia (PaCO2 >45 mmHg), 2)
patients admitted due to acute hypercapnic respiratory
failure requiring noninvasive mechanical ventilation, and 3)night.
Patients with hypoventilation due to other respiratory
diseases (neuromuscular, chronic obstructive pulmonary
disease [COPD], and obesity-hypoventilation syndrome)
were not included in the study. Having a tracheostomy for
airway access and discontinuation of NIHMV due to
noncompliance were exclusion criteria. The flow chart for
selecting patients is shown in Fig. 1.
The study protocol was approved by the hospital ethics
committee and written informed consent was obtained
from all patients.Variable measurements
Patients’ characteristics were systematically recorded in
a computer database. Forced spirometry15 and static
volumes (MasterLab Pro, Jaeger GmbH, Wuerzburg,
Germany) were obtained according to the European
Respiratory Society guidelines.16 In stable patients, base-
line respiratory function values were defined as the most
recent ones obtained prior to initiating NIHMV. In patients
who started NIHMV during acute respiratory failure, these
values were obtained once the patient had stabilized
before hospital discharge.
Samples for ABG testing were taken with the patient
breathing room air and processed with a pH and blood gas
analyser (IL-1306; Instrumentation Laboratories,Milan, Italy).
Comorbid conditions were recorded using the Charlson
Index.17 A score of 1e6 was assigned to each disease,
depending on its associated risk of death. In this study, all
patients had a minimal score of 1, since CWD was consid-
ered a chronic pulmonary disease.
Mechanical ventilation
NIHMV was initiated in the respiratory ward. Custom-made8
or commercial nasal masks were used. The choice of
Mortality in chest wall disease with NIV 1845ventilator type was based on the criteria of the attending
physician.18 The ventilator parameters were set, and the
efficacy of ventilation was evaluated taking into account
the patient’s tolerance, oxygen saturation, ABG while
awake at 1 h after starting ventilation, and nocturnal pulse
oximetry values.14 Patients were instructed in the
management of the ventilator and counseled in its
progressive use, at least during the entire night.
Follow-up
All patients were seen in the hospital outpatient clinic 1
month after starting NIHMV, and at intervals of 3e6 months
thereafter. At the 1-month visit, room-air ABG were
measured. Compliance with the prescription was reported
by the patient. A commercial supplier was in charge of
providing technical support at the patients’ home.
Patients remained in the study from the start of NIHMV up
to closure of follow-up, in December 2007. Closure was
earlier in patients whomoved out of the study district. These
patients were censored, but the information generated up to
the time of closurewas used in the study. The vital status and
cause of death were obtained from the patients’ medical
files, relatives, or primary care physicians.
Statistical analysis
Assessment of baseline homogeneity between survivors and
deceased patients was performedwith the unpaired t-test for
continuous variables, the ManneWhitney test for ordinal
variables, and Fisher’s exact test for qualitative variables.
Results are expressed as the mean  SD for quantitative
variables, and as frequencies and percentages for qualitative
and ordinal variables. The KaplaneMeier method was used to
estimate the survival functions and the Cox proportional
hazards model was used to perform the adjusted analysis.
The selection of independent variables for multivariate
Cox model was based on statistical significance obtained in
the univariate analysis (p < 0.10). A forward stepwise
procedure was used and results are expressed as hazard
ratios with 95% confidence intervals (CI).
Analyses were performed with SPSS for Windows, 15.0
(Statistical Package for the Social Sciences, Chicago, IL,
USA). Statistical significance for all tests was set at a two-
tailed p-value of 0.05.
Results
Clinical characteristics
Among 115 CWD patients starting NIHMV during 1996e2005,
110 were included in the study (Fig. 1). Characteristics of
the patients as a group and according to their vital status at
follow-up closure are shown in Table 1. At baseline, the
study cohort included 58% men with a mean age of w66
years. Spirometry showed a severe restrictive ventilatory
impairment with associated obstruction (FEV1/FVC <0.7) in
52 patients (47.3%). Obstruction was more prevalent in the
group with tuberculosis sequelae (60.7%) than in those with
kyphoscoliosis (30.6%) (pZ 0.002). Over 75% of participants
had at least one comorbid condition in addition to respi-
ratory disease (i.e., Charlson Index 2).Noninvasive home mechanical ventilation was started
during an admission for respiratory exacerbation in 17
patients (15.5%). Among the stable patients, NIHMV was
indicated with PaCO2 <45 mmHg in 6 cases (5.5%). Ninety-
three patients (84.5%) were treated with volume-cycled
ventilators and 17 (15.5%) with pressure-cycled ventilators.
Assist-control mode was used in 59 patients (53.6%), and
control mode in the remaining 51 (46.4%). In order to
overcome oral leaks, a chin strap was prescribed in 4
patients (3.6%). Twenty-four patients (21.8%) needed
oxygen coupled to the ventilator. Baseline PaO2 and PaCO2
indicated hypercapnic respiratory failure (PaO2 55.6  11.2
and PaCO2 56.4  9.0 mmHg) (Table 1). During mechanical
ventilation, PaCO2 returned to normal levels 1 h after
starting therapy (41.3  7.6 mmHg); 1 month later, with the
patient using home ventilation, diurnal PaCO2 was main-
tained at 46.4  4.9 mmHg while breathing room air.
Follow-up and mortality
Patients were followed-up for a median of 4.6 years
(interquartile range, 2.4e6.0). In 2 survivors who moved to
a different region, follow-up ended before December 2007,
at 7 and 23 months after starting NIHMV, respectively.
Another patient presented acute respiratory failure 9 years
after initiating NIHMV via nasal mask, and ventilation was
continued via tracheostomy. No patients were lost to
follow-up. The mean 1-month patient-reported compliance
with therapy was 9.3  1.9 h/day (9.6  1.8 in survivors vs.
8.8  2.0 in non-survivors p Z 0.055).
By the end of follow-up, 34 of 110 patients had died
(28.1%). Deaths were mainly due to respiratory causes
(64.7%) (Table 2). In the univariate analysis, patients who
died had higher comorbidity, total lung capacity, residual
volume, and PaCO2 at 1 month, and lower FEV1, FEV1/FVC
ratio, and PaO2 at 1 month (Table 1). There were no differ-
ences in ventilation characteristics, such as ventilator type
(volume- vs. pressure-cycled) or mode (assist-control vs.
control), between survivors and non-survivors (p Z 0.776
and pZ 0.303, respectively). There were no differences in
survival between patients with tuberculosis sequelae and
those with kyphoscoliosis (Table 1). The 5-year survival rate
was 0.69 (95% CI 0.55e0.83) in patients with tuberculosis
sequelae and 0.75 (0.60e0.89) in those with kyphoscoliosis.
Multivariate Cox analysis identified comorbidity and
PaCO2 at 1 month as independent predictors of mortality
(Table 3). The risk of death at least doubled with a Charlson
score 3, assuming the lower limit of the 95% CI as the
minimum risk associated with the present data. Regarding
PaCO2 value at 1 month, we defined several meaningful
cutoff points, such as 40, 45, and 50 mmHg (Table 4). A 1-
month PaCO2 of 50 mmHg yielded a more than 3-fold
increase in the probability of death. KaplaneMeier survival
curves for all-cause mortality according to PaCO2 at 1
month are shown in Fig. 2.
Discussion
In this study, a PaCO2 value of 50 mmHg at 1 month after
starting ventilation and the presence of comorbid condi-
tions as assessed by the Charlson Index were predictive
Table 1 Patient characteristics, univariate analyses.
Total series (n Z 110) Non-survivors (n Z 34) Survivors (n Z 76) p
Age, y 65.9  10.5 67.4  11.8 65.3  9.9 0.333
Sex, male 64 (58.2) 21 (61.8) 43 (56.6) 0.679
Smoker
Current 3 (2.7) 1 (2.9) 2 (2.6) 1.000
Past 46 (41.8) 14 (41.2) 32 (42.1)
Never 61 (55.5) 19 (55.9) 42 (55.3)
BMI, Kg/m2 27.2  4.9 26.4  5.3 27.5  4.7 0.252
Diagnosis
Tuberculosis sequelaea 61 (55.5) 19 (55.9) 42 (55.3) 1.000
Kyphoscoliosis 49 (44.5) 15 (44.1) 34 (44.7)
Comorbidity (Charlson Index)b
1 26 (23.9) 6 (17.6) 20 (26.7) 0.042*
2 46 (42.2) 12 (35.3) 34 (45.3)
3 37 (33.9) 16 (47.1) 21 (28)
FVC, % pred 32.4  10.5 30.3  8.5 33.3  11.2 0.161
FEV1, % pred 30.9  10.5 27.1  8.4 32.7  10.9 0.009*
FEV1/FVC 0.71  0.13 0.66  0.13 0.73  0.13 0.006*
TLC, % pred 62.3  18.5 69.3  19.5 59.5  17.4 0.019*
RV, % pred 100.4  43.8 115.9  47.3 94.0  41.0 0.028*
Baseline status
Stable 93 (84.5) 31 (91.2) 62 (81.6) 0.382
Acute 17 (15.5) 3 (8.8) 14 (18.4)
PaO2, mmHg
Baseline 55.6  11.2 53.2  9.6 56.6  11.7 0.146
One hour ventilation 72.8  13.0 70.2  12.7 73.9  13.1 0.193
At one month 64.3  9.1 61.4  8.8 65.6  8.9 0.025*
PaCO2, mmHg
Baseline 56.4  9.0 56.4  7.8 56.4  9.6 0.990
One hour ventilation 41.3  7.6 43.4  7.7 40.4  7.4 0.074
At one month 46.4  4.9 48.4  6.4 45.4  3.9 0.015*
D(A-a)O2, mmHg 25.7  11.7 28.1  8.6 24.7  12.8 0.163
Values are given as the mean  SD or n (%), unless otherwise indicated. % predZ % predicted; BMI Z body mass index; FVC Z forced
vital capacity; FEV1 Z forced expiratory volume in 1 s; TLC Z total lung capacity; RV Z residual volume; PaO2 Z arterial oxygen
tension; PaCO2 Z arterial carbon dioxide tension; D(A-a)O2 Z alveolar-arterial oxygen difference.
*p < 0.05.
a Mainly thoracoplasty and artificial pneumothorax.
b n Z 109.
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with NIHMV.
Chest wall disease is a frequent cause of respiratory
failure. The available data have shown considerable long-
term mortality in patients with CWD, particularly those
treated with LTOT.12,13 NIHMV is an effective treatment for
ventilatory failure in CWD patients, but few studies haveTable 2 Causes of death.
Respiratory
Cardiovascular diseases
Neoplasms
All other causesa
Total
a Sepsis (n Z 2), intestinal occlusion (n Z 2), and chronic renal faifocused on the long-term survival of this population and the
factors associated with mortality. The fact that
a percentage of our patients died during follow-up despite
treatment with NIHMV prompted us to investigate this
issue.
Our finding that an elevated PaCO2 at 1 month after
starting NIHMV is associated with mortality seems clinicallyn (%)
22 (64.7)
3 (8. 8)
4 (11.8)
5 (14.7)
34 (100)
lure (n Z 1).
Table 3 Prognostic factors according to the Cox model for mortality.
HR 95% CI p
Charlson Index
1 1
2 3.15 (0.91e10.96) 0.071
3 6.61 (1.96e22.35) 0.002
PaCO2 at 1 month, mmHg 1.13 (1.05e1.21) 0.001
HR Z Hazard ratio; CI Z Confidence interval.
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investigated in most studies11e13 but the prognostic value
of PaCO2 after starting NIHMV is poorly known. In a recently
online published study,19 the relationship between post-
NIHMV variables and withdrawal of this treatment in
a Japanese cohort of patients with tuberculosis sequelae
was analyzed. The authors found that PaCO2 levels at 3e6
months were associated with rates of NIHMV continuation.
The main difference between this cohort and ours is the
severity of the baseline hypercapnia at starting ventilation,
which was higher in the former. So, while baseline mean
PaCO2 in our patients was 56.4, it ranged between 64.6 and
90.2 mmHg in the Japanese cohort. Moreover, 50% of these
patients had PaCO2 levels higher than 60 mmHg at 3e6
months post-NIHMV. In spite of these differences, both
studies point out the relevance of PaCO2 measurement in
the control of patients stabilized after NIHMV instauration.
The need to check blood gases early in the follow-up of
these patients seems reasonable, because the initial
response observed during hospital admission should be
reassessed once ventilation is used at home. Hence,
delayed gasometric evaluation of NIHMV efficacy may
better reflect the patients’ response to NIHMV.20 Some
patients need a longer period of time to adapt to ventila-
tion, and in others delayed problems of leaks, compliance,
or patient-ventilator asynchrony may appear. According to
our results, inability to maintain PaCO2 <50 mmHg after 1
month of NIHMV may be a reflection of these problems or
simply indicate the limitation of this therapy to revert
respiratory failure in certain patients, thus justifying their
higher mortality. This is supported by the fact that 65% of
the deaths had a respiratory origin. ABG before starting
ventilation were not associated with mortality in our study.
This data likely express baseline severity, but their prog-
nostic value is unclear, because NIHMV was effective in
reverting ventilatory failure in most cases, and therefore,
the problem threatening the patients’ evolution would
have been modified. Our results highlight the value of
short-term surveillance that includes ABG measurement in
the management of CWD patients undergoing NIHMV. This
suggests that home ventilation should be checked earlyTable 4 Hazard ratio for all-cause mortality according to diffe
HR
PaCO2, mmHg
40 2.78
45 1.8
50 3.42
HR Z Hazard ratio; CI Z Confidence interval.after it is started and readjusted when hypercapnia is
detected.
We observed a consistent, progressive relationship
between comorbidity expressed with the Charlson Index
and mortality. Comorbidity is likely to influence mortality in
several ways. First, it may have provoked an increase in the
percentage of fatal nonrespiratory complications, since 35%
of deaths were not related to respiratory causes. Second,
the presence of comorbid conditions could make a patient
more susceptible to respiratory exacerbations,21 which
were the most common cause of death in our series. And
last, the presence of additional diseases might have
a deleterious effect on the efficacy of NIHMV or make
compliance more difficult. In any case, our results indicate
the need for a careful, comprehensive evaluation of
patients with CWD to improve their overall health status
and not only limit the therapeutic effort to reverting
ventilatory failure.
The patients undergoing NIHMV in the present study had
a severe restrictive ventilatory pattern, and in 47.3% of
cases, mainly those with tuberculosis sequelae, airway
obstruction was also present. Obstruction has been
described as a functional respiratory complication after
tuberculosis.22,23 Among our post-tuberculosis patients with
this complication, the functional impairment was likely due
to tuberculosis alone in 44% of patients, while smoking
could have been a contributory factor in the 56% remainder.
We attempted to ascertain the influence of airway
obstruction on mortality in the 110 patients studied.
Although a significant difference was seen in the univariate
approach, there was no association between obstruction
and mortality in the multivariate model. The reason why
obstruction did not influence mortality may be due to the
fact that this impairment was appropriately treated.
The present study has several potential limitations. The
lengthy period of inclusion and follow-up, necessarily
required in a survival study, implies that changes in the
management of the population included may have occurred
over time. For example, the current indications for NIHMV
include patients with obesity-hypoventilation syndrome
and some patients with COPD. Nonetheless, the indicationsrent cutoff points for 1-month PaCO2 in the Cox model.
95% CI p
(0.35e22.13) 0.333
(0.85e3.82) 0.123
(1.62e7.2) 0.001
Figure 2 KaplaneMeier survival curves for all-cause
mortality according to PaCO2 at 1 month of home ventilation.
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the years,24,25 and we do not believe this factor posed
a problem in the study. Another potentially conflicting
point is the type of ventilator used. Classically, patients
with CWD have been treated with volume-cycled ventila-
tors,3 but in recent years there has been an increasing use
of pressure-cycled ventilators.25 In our study, pressure-
cycled ventilators were used in only 15% of the patients.
The scientific evidence reported to date has not shown
differences in the efficacy of ventilation depending on the
type of cycling26; thus, it is reasonable to assume that this
variable would not have an influence on survival. Notwith-
standing, we believe the prognostic data obtained in our
study should be confirmed in CWD patients who are mainly
treated with pressure-cycled ventilators.
In conclusion, our results suggest that PaCO2 levels
50 mmHg at 1 month after starting noninvasive home
mechanical ventilation and the presence of comorbid
conditions are risk factors for mortality in patients with
chest wall disease. We believe these results are relevant for
the clinical management of these patients, particularly
because they underscore the importance of early detection
of suboptimal home ventilation, which may be amenable to
correction.
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